| Abstrakt: |
A clinical appraisal of efficacy and tolerability of taxol (T) and a generic drug--paclitaxel--LANCE (P)--was carried out in two groups of patients with recurrences (9) or platinum-refractory ovarian carcinoma (17). In group I, patients aged 19-71 (mean age--47 yrs) had received 6-7 courses, while, in group II, patients aged 44-72 (mean age--52 yrs) who suffered tumor progression--15.0 courses of various chemotherapeutic regimens. Following standard premedication, T and P were injected 135 mg/sq., intravenously, dropwise, during 3 hrs, as a rule, either concurrently with platinum drugs or with hemzar. In the final analysis, there was no clinically significant difference in overall response--44-30% and 44-48%, respectively, nor any significant difference in side-effect incidence was reported. |
